OUR PRODUCT
MyProstateScore 2.0
Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.
Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.
MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for providers and both biopsy naïve and prior negative patients.
You deserve the next generation in prostate cancer risk prediction for men’s health.
How It Works
Our Science. Clear Results. Your Decision.
A simple urine test that shines a highly sensitive light on a patient’s actual risk of prostate cancer when PSA is elevated. Our data models have combined those clinical factors most relevant for both biopsy naïve and prior negative patient populations. Our goal is to provide a solution with zero surprises for all involved.
MPS2
Early Prostate Cancer Risk Assessment
One in eight men will receive a prostate cancer diagnosis during their lifetime. The good news? Survival is nearly 100% when diagnosed early and contained within the prostate. When it spreads, however, the five-year survival is just 31%.
Early detection is critical for you and your family.
You can avoid subjective, invasive tests and receive a highly accurate prostate cancer screening to assess your current risk.
MyProstateScore 2.0 can give you and your urologist accurate data to make a personalized healthcare decision for you.
Stay Up-To-Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
LynxDx Relocates to New and Improved Headquarters to Prime Next Phase of Growth
ANN ARBOR, MI – LynxDx, an Ann Arbor-based genomics [...]
Why Prostate Cancer Hits Veterans Hard — and What’s Being Done About It
Veterans are at high risk of prostate cancer, yet there are important initiatives underway. A 2022 law expands care and research at the VHA.
Movember at 20: Beyond the Mustache
From a friendly dare to a global movement, discover how Movember raised $1 billion for prostate cancer and other men's health research.